Surgery Partners, Inc. (SGRY) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Positive elements include strategic M&A plans, new facility investments, and a share buyback program, indicating confidence. However, challenges such as payer mix issues, slow revenue growth, and cautious guidance offset these positives. The Q&A reveals management's plans to address these challenges, but uncertainty remains. Given the company's market cap and the balance of positive and negative factors, the stock price is likely to remain stable in the short term, resulting in a neutral rating.
Key Financial Performance
Full Year Net Revenue $3.3 billion, up 6.2% year-over-year. Reasons for change: Same facility revenue growth of 4.9% and momentum in the first half of the year, though offset by significant headwinds in the second half.
Full Year Adjusted EBITDA $526 million, up 3.5% year-over-year. Reasons for change: Margin compression of 40 basis points and challenges in the second half of the year, including slower case growth and payer mix trends.
Adjusted EBITDA Margin 15.9%, reflecting a 40 basis points compression year-over-year. Reasons for change: Slower-than-expected case growth, payer mix shifts, and anesthesia dynamics in specific markets.
Surgical Cases Performed 670,000 cases in 2025 compared to 656,000 cases in 2024, a 2% increase. Reasons for change: Organic growth and a strategic shift towards higher acuity procedures.
Orthopedic Cases 42,000 cases in Q4, with total joint cases growing 15% in Q4 and 19% year-to-date compared to last year. Reasons for change: Focus on high-acuity procedures and investment in robotics and physician recruitment.
Capital Deployment for Acquisitions $182 million in 2025, below the target of $200 million. Reasons for change: Disciplined approach to capital allocation and back-end weighted deployment.
Same-Facility Revenue Growth 3.5% in Q4. Reasons for change: 1.3% same-facility case growth and 2.1% rate growth, though impacted by payer mix softening.
Operating Cash Flows $274 million in 2025, lower than 2024. Reasons for change: Higher interest costs on corporate debt and slower-than-anticipated earnings growth.
Salaries and Wages 28.7% of net revenue in Q4, nearly 100 basis points higher than the prior year. Reasons for change: Payer mix changes and marginally higher health benefit costs.
Supply Costs 27% of net revenue in Q4, up 120 basis points from last year. Reasons for change: Shift in payer mix.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Orthopedic Specialties: Focused on expanding surgical case volumes and shifting towards higher acuity procedures, including total joint replacements. Performed over 42,000 orthopedic cases in Q4, with total joint cases growing 15% in Q4 and 19% year-to-date.
Robotics Investment: Added 6 surgical robots in 2025, bringing the total to 74, enabling complex procedures.
Physician Recruitment: Recruited almost 700 physicians in 2025, though newer physicians contributed to a higher proportion of Medicare patients, impacting payer mix.
De Novo Facilities: Opened 8 new facilities in 2025, with 5 more under construction and over a dozen in the pipeline. These facilities focus on high-growth markets and higher acuity specialties.
M&A Activity: Deployed $182 million towards acquisitions in 2025, slightly below the $200 million target. Acquisitions were made at attractive valuations and are expected to support future growth.
Operational Challenges: Faced headwinds in 3 surgical hospital markets due to slower case growth, payer mix shifts, and anesthesia dynamics. Margins compressed due to labor and anesthesia costs.
Portfolio Optimization: Focused on divesting or partnering with facilities outside the core short-stay surgical strategy. Example: Baylor Scott & White joint venture in Bryan, Texas.
Share Buyback Program: Authorized up to $200 million for share repurchase, reflecting confidence in the company's future.
Leadership Changes: Appointed Lloyd Dean as a new director and invested in new leadership for underperforming facilities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue and EBITDA Performance: Full year net revenue was at the low end of expectations at $3.3 billion, with adjusted EBITDA significantly below expectations, reflecting margin compression and underperformance in the second half of the year.
Surgical Hospital Market Challenges: Earnings shortfall was concentrated in three surgical hospital markets due to softer-than-expected case growth, payer mix shifts, and anesthesia dynamics, creating outsized pressure.
Physician Transitions: Retirement or departure of experienced physicians led to a higher proportion of Medicare patients and slower ramp-up of newly recruited physicians, contributing to payer mix pressure and declining commercial payer revenue.
Cost Structure and Labor Expenses: Labor expenses and anesthesia coverage costs did not adjust quickly enough to changing payer mix, leading to incremental margin pressure in certain markets.
State-Specific Provider Taxes and Tariffs: New hospital provider taxes in three markets and potential tariff exposure are expected to pressure earnings in 2026 by $12 million.
Portfolio Optimization Risks: Ongoing portfolio optimization efforts, including divestitures and partnerships, may lead to reduced reported revenue and operational complexity during transitions.
M&A and Capital Deployment Timing: M&A activity was back-end weighted in 2025, leading to lower in-year impact, and future M&A timing remains uncertain.
Interest Costs and Debt: Higher interest costs on corporate debt impacted operating cash flows, with a $42 million year-over-year increase in interest expenses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Guidance: The company projects net revenue in the range of $3.35 billion to $3.45 billion, representing single-digit year-over-year growth. Same-facility revenue growth is expected to be 3% to 5%.
2026 Adjusted EBITDA Guidance: Initial guidance for adjusted EBITDA is at least $530 million, reflecting a growth of at least 0.7%. This includes anticipated headwinds such as state-specific hospital provider taxes ($8 million impact) and tariffs ($4 million impact).
M&A and Capital Deployment: The company plans to deploy at least $200 million towards mergers and acquisitions (M&A) in 2026, focusing on opportunities aligned with its short-stay surgical strategy. However, the impact of M&A is not included in the initial guidance.
Portfolio Optimization: The company is advancing its portfolio optimization strategy, focusing on divesting or partnering with facilities that do not align with its core short-stay surgical strategy. Key resolutions are expected within the first half of 2026.
De Novo Facility Development: The company plans to continue developing de novo facilities, with 5 currently under construction and more than a dozen in the development pipeline. These facilities are expected to contribute to long-term growth.
Operational Efficiency and Margin Expansion: The company aims to improve operational efficiency through supply chain enhancements, revenue cycle operations, and targeted cost reduction plans to overcome near-term headwinds and achieve steady margin expansion.
Cash Flow and Debt Management: Cash flow from operations is expected to increase in 2026, driven by adjusted EBITDA growth and working capital management. The company also aims to reduce leverage and improve cash flows through portfolio optimization efforts.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Program: The Board authorized the company to repurchase up to $200 million of the company's common stock. This authorization reflects the Board's confidence in the company's future and its strategy to deliver shareholder value. Bain Capital has informed that they will not be a seller in this share buyback program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about the dynamic between muted volume growth and steady demand fundamentals, along with the payer mix situation and specific market challenges?
A:The CEO emphasized the company's strong value proposition in the healthcare system and its ability to grow despite challenges. Organic growth is guided at 4% or more, which is at the lower end of the range due to current headwinds. The payer mix has been steady historically, but unique events in Q4 caused pressure, particularly in three specific markets. These markets faced distinct challenges, including competitors limiting Medicare Advantage access, growth concentrated in government patients, and physician transitions in rural areas. Plans are in place to address these issues, and the company does not expect a repeat of these pressures.
Q:How is the company balancing its levered balance sheet with a $200 million acquisition target and a new share buyback program?
A:The CEO stated that the $200 million share buyback authorization reflects the Board's measured approach to capital allocation. The company is focused on maximizing shareholder value while balancing M&A, debt reduction, and share repurchases. The buyback is seen as an attractive option given current share prices, but deleveraging remains a priority. The approval also indicates confidence in portfolio optimization efforts.
Q:What is the breakdown between price and volume in the 3% same-store revenue guidance?
A:The breakdown is roughly even between price and volume.
Q:When can the company expect to see positive signs from influencing the payer mix, and what tools are being used?
A:The company is working with physician partners to sharpen processes around access for commercial patients. While Q1 is typically a high Medicare quarter, improvements in commercial mix are expected to be seen in the back half of the year. Tools include coordinated physician scheduling, ease of access for commercial patients, and reinforcing the company's value proposition.
Q:What is the company's assumption for recovery in surgical hospital markets, and how does it play out throughout the year?
A:The company has allowed some pressure from 2025 to flow into 2026 guidance but does not expect a repeat of the degradation seen in 2025. Surgical hospitals are viewed as strong assets with a commercial mix much better than traditional hospitals. New leadership and turnaround plans are in place to address challenges.
Q:What has been the historical M&A contribution to EBITDA, and how does it compare to current assumptions?
A:Historically, the company has guided to $200 million to $250 million of EBITDA from M&A, assuming an 8x multiple at midyear convention. The current guidance does not assume unannounced M&A, which is seen as prudent.
Q:Is the Q4 issue an extension of Q3 dynamics, and is it concentrated in surgical hospitals or also affecting ASCs?
A:The Q4 issue is an extension of Q3 dynamics but became more concentrated in surgical hospitals, particularly in three markets. ASCs were steady and not significantly impacted.
Q:Is the $200 million share repurchase authorization contingent on divestitures?
A:The authorization is available now but will depend on market conditions and portfolio optimization efforts. The company remains focused on deleveraging.
Q:How would you characterize patient throughput and incremental costs to manage additional throughput?
A:The company expects ample demand for its services and projects 4%+ organic growth. Weather-related impacts are acknowledged but not expected to materially affect long-term trends. Incremental costs are managed through efficiency improvements.
Q:What are the company's plans for service line expansion, and which specialties are promising?
A:The company is focused on orthopedic opportunities, including total joints and spine, which showed strong growth. Vascular procedures are also a promising area. Other specialties like GI, ophthalmology, general surgery, and urology are being pursued for growth.
Q:What is the company's confidence in resolving payer mix issues, and what is the expected trajectory?
A:The company has identified the issues and has plans to address them. While Q1 is expected to show continued pressure, improvements are anticipated throughout the year. The company remains confident in its ability to compete for commercial patients.
Q:How does the phaseout of the inpatient-only list impact cardiology procedures?
A:The phaseout is seen as a positive backdrop, allowing physicians to decide on the appropriate site of care. While cardiology transitions may take longer due to state restrictions and physician employment, the company sees significant long-term opportunities in this area.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific revenue impact of the three markets facing challenges and the exact timing for resolving payer mix issues. Additionally, while they acknowledged weather-related impacts, they did not provide detailed data on how it affected Q1 performance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Lloyd
Partners Full
action
activity line
alignment
anesthesia dynamic
capital allocation
capital deployment
case payer
case shift
convergence
dynamic portfolio
effort outlook
enterprise
framework
health care
hospital market
hospital provider
improvement volume
incentive
interest debt
margin compression
market dynamic
need
optimization effort
optimization process
payer mix
portfolio optimization
pressure payer
proceeds
provider tax
reduction
shareholder value
structure
term margin
term market
transition
value creation
SGRY Transcript
Surgery Partners, Inc. (SGRY) Q4 2025 Earnings Call Transcript
Unknown3-3
The earnings call presents a mixed picture. Positive elements include strategic M&A plans, new facility investments, and a share buyback program, indicating confidence. However, challenges such as payer mix issues, slow revenue growth, and cautious guidance offset these positives. The Q&A reveals management's plans to address these challenges, but uncertainty remains. Given the company's market cap and the balance of positive and negative factors, the stock price is likely to remain stable in the short term, resulting in a neutral rating.
Surgery Partners, Inc. (SGRY) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call presents mixed signals. Strong growth in orthopedic procedures and revenue guidance reaffirmation are positive. However, weaker-than-expected demand, a reduction in acquisition spending, and a $20 million EBITDA guidance cut are concerning. Management's uncertainty about macroeconomic factors and payer mix changes adds to the ambiguity. The market cap suggests moderate sensitivity, leading to a neutral prediction.
Surgery Partners, Inc. (SGRY) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call highlights strong financial performance, with revenue and EBITDA growth, strategic expansion in ASC, and positive outlooks on partnerships and market trends. The Q&A reveals stable payer behavior, promising robotics investments, and a large TAM. Despite some management vagueness and lower EBITDA guidance, the overall sentiment is positive, supported by growth initiatives and reaffirmed guidance. Given the market cap, a 2%-8% stock price increase is expected.
Surgery Partners, Inc. (SGRY) Q1 2025 Earnings Call Transcript
Positive5-12
The earnings call summary shows strong financial performance with 7% EBITDA growth, 5.2% same-facility revenue growth, and stable debt metrics. The Q&A section confirms constructive payer negotiations and consistent payer mix, with positive outlooks for cash flow and M&A activities. Despite some unclear responses, the overall sentiment is positive, supported by improved liquidity and strategic growth plans. Given the company's market cap, the stock is likely to experience a moderate positive reaction, estimated between 2% to 8%.
SGRY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
